Knight-Swift Q2 Earnings Surpass Estimates, Improve Year Over Year — Positive

KNX   Zacks Investment Research — August 13, 2025

KNX's second-quarter 2025 earnings improve year over year while revenues decline.

image for news Knight-Swift Q2 Earnings Surpass Estimates, Improve Year Over Year

Guidewire Rises 23% YTD: Where Will the Stock Head From Here? — Positive

GWRE   Zacks Investment Research — August 13, 2025

GWRE is up 23% year to date as cloud momentum builds, but rising costs and valuation spur caution among investors.

image for news Guidewire Rises 23% YTD: Where Will the Stock Head From Here?

Century Aluminum Reports Q2 Loss, Misses Revenue Estimates — Negative

CENX   Zacks Investment Research — August 13, 2025

CENX posts second-quarter loss and misses estimates despite higher aluminum shipments and improved regional premiums.

image for news Century Aluminum Reports Q2 Loss, Misses Revenue Estimates

2 Air Freight & Cargo Stocks to Keep An Eye On Amid Demand Woes — Negative

FDX  GXO   Zacks Investment Research — August 13, 2025

Headwinds like weak demand, high inflation & geopolitical woes hurt the Zacks Transportation Air Freight & Cargo industry. FDX & GXO are likely to stand out.

image for news 2 Air Freight & Cargo Stocks to Keep An Eye On Amid Demand Woes

ATLANTA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information, including allegations that: (1) Defendants recklessly overstated the IGNYTE trial's prospects, given material issues that defendants knew or should have known of, which resulted in the FDA deeming the IGNYTE trial inadequate and not well-controlled; and (2) as a result, defendants' statements about Replimune's business, operations, and prospects were materially false and misleading and/or lacked a reasonable …

image for news INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Replimune Group (REPL) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm

Trading Or Investing In Oxford Lane Capital Corporation — Neutral

OXLC   Seeking Alpha — August 13, 2025

I aim to inform investors about collateralized loan obligations (CLOs) and their fundamentals. I will analyze some of the most popular CLO symbols to provide actionable insights. The article explores the structure and investment potential of CLOs for retail investors.

image for news Trading Or Investing In Oxford Lane Capital Corporation

“The reason this announcement is so significant is that Amazon has yet to displace incumbents in the grocery category, at least for perishables,” Wedbush analysts said.

image for news Why Amazon's ‘major' grocery expansion is bad news for delivery apps and retailers

Will Royal Caribbean's Fleet Growth Anchor Its 2025 Demand Strategy? — Positive

RCL   Zacks Investment Research — August 13, 2025

RCL's steady rollout of new ships is fueling pricing power, guest growth and premium yields for 2025.

image for news Will Royal Caribbean's Fleet Growth Anchor Its 2025 Demand Strategy?

Online Home Goods Retailer Soars to 52-Week High — Positive

W   Zacks Investment Research — August 13, 2025

Wayfair is rolling out new AI-powered features to create a more seamless experience for customers.

image for news Online Home Goods Retailer Soars to 52-Week High

Theravance's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y — Positive

TBPH   Zacks Investment Research — August 13, 2025

TBPH posts better-than-expected second-quarter 2025 results, boosted by Yupelri sales and licensing gains.

image for news Theravance's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y

Should You Buy, Hold, or Sell NuScale Power Stock Post Q2 Earnings? — Neutral

SMR   Zacks Investment Research — August 13, 2025

NuScale Power Q2 revenues surge 733% on SMR advances and new NRC approval, but steep valuation and tough competition warrant a cautious approach for the stock.

image for news Should You Buy, Hold, or Sell NuScale Power Stock Post Q2 Earnings?

ALAB Jumps 113% in a Month: Here's Why the Stock is Still a Buy — Positive

ALAB   Zacks Investment Research — August 13, 2025

Astera Labs soars 112.6% in a month on booming demand, record Q2 growth and bullish Q3 guidance fueled by next-gen AI connectivity.

image for news ALAB Jumps 113% in a Month: Here's Why the Stock is Still a Buy

Can Urban Outfitters Maintain Its Winning Streak Across All Channels? — Positive

URBN   Zacks Investment Research — August 13, 2025

URBN posts strong retail and wholesale gains in the first quarter, with all brands delivering positive comps and wholesale surging over 24%.

image for news Can Urban Outfitters Maintain Its Winning Streak Across All Channels?

Will Digital Engagement Drive Starbucks' Customer Spend Growth? — Positive

SBUX   Zacks Investment Research — August 13, 2025

SBUX leverages loyalty, mobile ordering and delivery to make digital engagement drive customer spend growth.

image for news Will Digital Engagement Drive Starbucks' Customer Spend Growth?

Werner Rewards Shareholders With New Share Repurchase Authorization — Positive

WERN   Zacks Investment Research — August 13, 2025

WERN's consistent efforts to reward its shareholders through dividend payments and share repurchases highlight its financial bliss.

image for news Werner Rewards Shareholders With New Share Repurchase Authorization

PEGA Trades 16% Below 52-Week High: Buy, Sell or Hold the Stock? — Neutral

PEGA   Zacks Investment Research — August 13, 2025

Pegasystems' robust ACV growth and AI-driven solutions fuel long-term potential, but competition and valuation pressures weigh on near-term performance.

image for news PEGA Trades 16% Below 52-Week High: Buy, Sell or Hold the Stock?

A Cure For Novo Nordisk — Negative

NVO   Seeking Alpha — August 13, 2025

NVO has sector headwinds and product growth concerns. These problems don't have an easy solution and the market has administered its own cure - a 70% drop. The bad news should be mostly priced in. $47.50 is a strong technical support; I expect stabilization and a gradual recovery from this level.

image for news A Cure For Novo Nordisk

Stran & Company, Inc. (SWAG) Q2 2025 Earnings Conference Call Transcript — Neutral

SWAG   Seeking Alpha — August 13, 2025

Stran & Company, Inc. (NASDAQ:SWAG ) Q2 2025 Earnings Conference August 13, 2025 10:00 AM ET Company Participants Andrew Shape - Co-Founder, President, CEO & Director David Browner - Chief Financial Officer Conference Call Participants Alexandra Schilt - Unidentified Company Operator [indiscernible] Please note, this conference is being recorded. I will now turn the conference over to your host, Alexandra Schilt of Crescendo Communications.

image for news Stran & Company, Inc. (SWAG) Q2 2025 Earnings Conference Call Transcript

M-tron Industries, Inc. (MPTI) Q2 2025 Earnings Call Transcript — Neutral

MPTI   Seeking Alpha — August 13, 2025

M-tron Industries, Inc. (NYSE:MPTI ) Q2 2025 Earnings Conference Call August 13, 2025 10:30 AM ET Company Participants Cameron Pforr - CFO & Interim CEO Linda M. Biles - Executive VP of Finance & Secretary Conference Call Participants Anja Marie Theresa Soderstrom - Sidoti & Company, LLC Gregory McKinley - Unidentified Company Operator Thank you for standing by.

image for news M-tron Industries, Inc. (MPTI) Q2 2025 Earnings Call Transcript

Charlotte's Web Holdings, Inc. (OTCQX:CWBHF) Q2 2025 Earnings Conference August 13, 2025 11:00 AM ET Company Participants Cory Pala - Director of Investor Relations Erika Lind - CFO & Principal Accounting Officer William J. Morachnick - CEO & Non-Independent Director Conference Call Participants Pablo Ernesto Zuanic - Zuanic & Associates Operator Good morning, ladies and gentlemen, and welcome to the Charlotte's Web Holdings, Inc. 2025 Second Quarter Conference Call.

image for news Charlotte's Web Holdings, Inc. (CWBHF) Q2 2025 Earnings Conference Call Transcript